NO325416B1 - Kombinasjon som omfatter en signaltransduksjoninhibitor og et epotilonderivat, farmasoytisk sammensetning som inneholder nevnte kombinasjon, samt anvendelse derav ved behandling av en proliferativ sykdom. - Google Patents

Kombinasjon som omfatter en signaltransduksjoninhibitor og et epotilonderivat, farmasoytisk sammensetning som inneholder nevnte kombinasjon, samt anvendelse derav ved behandling av en proliferativ sykdom. Download PDF

Info

Publication number: NO325416B1
Authority: NO; Norway
Prior art keywords: hydrogen; alkyl; formula; combination; pharmaceutically acceptable
Prior art date: 2001-02-27

Application number

NO20033769A

Other languages

English (en)

Norwegian (no)

Other versions

NO20033769D0 (no

NO20033769L (no

Inventor

Carl-Henrik Heldin

Peter Traxler

Terence O'reilly

Ralf Brandt

Arne Ostman

Kristian Pietras

John David Rothermel

Markus Wartmann

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-27

Filing date

2003-08-25

Publication date

2008-04-21

2001-02-27 Priority claimed from GBGB0104840.4A external-priority patent/GB0104840D0/en

2003-08-25 Application filed by Novartis Ag filed Critical Novartis Ag

2003-08-25 Publication of NO20033769D0 publication Critical patent/NO20033769D0/no

2003-08-25 Publication of NO20033769L publication Critical patent/NO20033769L/no

2008-04-21 Publication of NO325416B1 publication Critical patent/NO325416B1/no

Links

238000011282 treatment Methods 0.000 title claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
150000003883 epothilone derivatives Chemical class 0.000 title claims description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 18
201000010099 disease Diseases 0.000 title claims description 15
230000002062 proliferating effect Effects 0.000 title claims description 14
239000003112 inhibitor Substances 0.000 title claims description 12
230000019491 signal transduction Effects 0.000 title claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 39
239000001257 hydrogen Substances 0.000 claims description 39
206010028980 Neoplasm Diseases 0.000 claims description 27
150000003839 salts Chemical class 0.000 claims description 27
125000000217 alkyl group Chemical group 0.000 claims description 25
150000001875 compounds Chemical class 0.000 claims description 22
239000004480 active ingredient Substances 0.000 claims description 18
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
108010055723 PDGF receptor tyrosine kinase Proteins 0.000 claims description 14
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 13
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 12
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 12
239000003937 drug carrier Substances 0.000 claims description 12
125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 10
150000002431 hydrogen Chemical class 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
229940126062 Compound A Drugs 0.000 claims description 9
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 9
-1 N-oxido-pyridyl Chemical group 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
125000004076 pyridyl group Chemical group 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
108091008606 PDGF receptors Proteins 0.000 claims description 4
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 3
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
125000001544 thienyl group Chemical group 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
150000004046 2-(N-anilino)pyrimidines Chemical class 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000006413 ring segment Chemical group 0.000 claims description 2
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract description 7
QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 30
QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 29
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 29
230000000694 effects Effects 0.000 description 20
241000699670 Mus sp. Species 0.000 description 9
230000009286 beneficial effect Effects 0.000 description 9
239000002253 acid Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 6
238000012360 testing method Methods 0.000 description 6
XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000007795 chemical reaction product Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
208000024770 Thyroid neoplasm Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
229940125714 antidiarrheal agent Drugs 0.000 description 3
239000003793 antidiarrheal agent Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
238000009097 single-agent therapy Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
201000002510 thyroid cancer Diseases 0.000 description 3
RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 2
229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
150000003951 lactams Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229940005483 opioid analgesics Drugs 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000002419 Motilin Human genes 0.000 description 1
101800002372 Motilin Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
239000008896 Opium Substances 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000037844 advanced solid tumor Diseases 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
229940093265 berberine Drugs 0.000 description 1
QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
229960000782 bismuth subsalicylate Drugs 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229960005493 difenoxin Drugs 0.000 description 1
UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229960004192 diphenoxylate Drugs 0.000 description 1
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229930013356 epothilone Natural products 0.000 description 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000003304 gavage Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000003908 liver function Effects 0.000 description 1
229960001571 loperamide Drugs 0.000 description 1
RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000000472 muscarinic agonist Substances 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960002700 octreotide Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
229960001027 opium Drugs 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000009703 regulation of cell differentiation Effects 0.000 description 1
230000025053 regulation of cell proliferation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20033769A 2001-02-27 2003-08-25 Kombinasjon som omfatter en signaltransduksjoninhibitor og et epotilonderivat, farmasoytisk sammensetning som inneholder nevnte kombinasjon, samt anvendelse derav ved behandling av en proliferativ sykdom. NO325416B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0104840.4A GB0104840D0 (en)	2001-02-27	2001-02-27	Use of organic compounds
US33904001P	2001-10-30	2001-10-30
PCT/EP2002/002049 WO2002067941A2 (en)	2001-02-27	2002-02-26	Combination comprising a signal transduction inhibitor and an epothilone derivative

Publications (3)

Publication Number	Publication Date
NO20033769D0 NO20033769D0 (no)	2003-08-25
NO20033769L NO20033769L (no)	2003-08-25
NO325416B1 true NO325416B1 (no)	2008-04-21

Family

ID=26245767

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033769A NO325416B1 (no)	2001-02-27	2003-08-25	Kombinasjon som omfatter en signaltransduksjoninhibitor og et epotilonderivat, farmasoytisk sammensetning som inneholder nevnte kombinasjon, samt anvendelse derav ved behandling av en proliferativ sykdom.

Country Status (23)

Country	Link
US (1)	US7723339B2 (sk)
EP (1)	EP1385522B1 (sk)
JP (1)	JP4499359B2 (sk)
KR (1)	KR100848197B1 (sk)
CN (1)	CN1511036B (sk)
AT (1)	ATE434438T1 (sk)
AU (1)	AU2002308218B2 (sk)
BR (1)	BR0207649A (sk)
CA (1)	CA2439268C (sk)
CY (1)	CY1109347T1 (sk)
DE (1)	DE60232719D1 (sk)
DK (1)	DK1385522T3 (sk)
ES (1)	ES2326264T3 (sk)
HK (1)	HK1062266A1 (sk)
IL (2)	IL157466A0 (sk)
MX (1)	MXPA03007729A (sk)
NO (1)	NO325416B1 (sk)
NZ (1)	NZ527764A (sk)
PL (1)	PL207197B1 (sk)
PT (1)	PT1385522E (sk)
RU (1)	RU2313345C2 (sk)
SK (1)	SK287489B6 (sk)
WO (1)	WO2002067941A2 (sk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69734362T2 (de)	1996-12-03	2006-07-20	Sloan-Kettering Institute For Cancer Research	Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
JP2004529904A (ja)	2001-03-14	2004-09-30	ブリストル−マイヤーズ　スクイブ　カンパニー	増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ
MXPA03010401A (es) *	2001-05-16	2004-03-09	Novartis Ag	Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
EP1704863A3 (en) *	2001-05-16	2010-11-24	Novartis AG	Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
JP2005507424A (ja) *	2001-10-29	2005-03-17	ノバルティスアクチエンゲゼルシャフト	固形腫瘍の処置における７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体の使用
SI1767535T1 (sl)	2002-08-23	2010-03-31	Sloan Kettering Inst Cancer	Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JO2596B1 (en) *	2004-11-30	2011-02-27	نوفارتيس ايه جي	Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
EP1856255A4 (en)	2005-02-11	2010-01-27	Univ Southern California	METHODS OF EXPRESSING PROTEINS WITH DISULFIDE BRIDGES
WO2007130501A2 (en) *	2006-05-01	2007-11-15	University Of Southern California	Combination therapy for treatment of cancer
WO2010056901A2 (en)	2008-11-13	2010-05-20	University Of Southern California	Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en)	2009-03-24	2010-09-30	Life & Brain Gmbh	Promotion of neuronal integration in neural stem cell grafts
EA035193B1 (ru)	2010-05-18	2020-05-14	Серулин Фарма Инк.	Композиции и способы лечения аутоиммунных и других заболеваний

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989006692A1 (en) *	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
TW225528B (sk)	1992-04-03	1994-06-21	Ciba Geigy Ag
CZ1598A3 (cs) *	1995-07-06	1998-04-15	Novartis Ag	Pyrrolopyrimidiny a způsoby jejich přípravy
NZ335383A (en)	1996-11-18	2000-10-27	Biotechnolog Forschung Gmbh	Epothilone C,D,E and F for plant protection and cytostatic effects shown in kidney cells
CO4940418A1 (es) *	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6302838B1 (en) *	1998-02-25	2001-10-16	Novartis Ag	Cancer treatment with epothilones
WO2000000485A1 (de) *	1998-06-30	2000-01-06	Schering Aktiengesellschaft	Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
CA2360952A1 (en) *	1999-02-11	2000-08-17	Schering Aktiengesellschaft	Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
DE19908760A1 (de) *	1999-02-18	2000-08-24	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

2002
- 2002-02-26 PL PL363288A patent/PL207197B1/pl not_active IP Right Cessation
- 2002-02-26 KR KR1020037011205A patent/KR100848197B1/ko not_active IP Right Cessation
- 2002-02-26 RU RU2003127392/15A patent/RU2313345C2/ru not_active IP Right Cessation
- 2002-02-26 MX MXPA03007729A patent/MXPA03007729A/es active IP Right Grant
- 2002-02-26 DE DE60232719T patent/DE60232719D1/de not_active Expired - Lifetime
- 2002-02-26 SK SK1071-2003A patent/SK287489B6/sk not_active IP Right Cessation
- 2002-02-26 CA CA002439268A patent/CA2439268C/en not_active Expired - Fee Related
- 2002-02-26 IL IL15746602A patent/IL157466A0/xx unknown
- 2002-02-26 AU AU2002308218A patent/AU2002308218B2/en not_active Ceased
- 2002-02-26 US US10/469,367 patent/US7723339B2/en not_active Expired - Fee Related
- 2002-02-26 ES ES02744903T patent/ES2326264T3/es not_active Expired - Lifetime
- 2002-02-26 EP EP02744903A patent/EP1385522B1/en not_active Expired - Lifetime
- 2002-02-26 WO PCT/EP2002/002049 patent/WO2002067941A2/en active IP Right Grant
- 2002-02-26 CN CN028056086A patent/CN1511036B/zh not_active Expired - Fee Related
- 2002-02-26 JP JP2002567308A patent/JP4499359B2/ja not_active Expired - Fee Related
- 2002-02-26 BR BR0207649-7A patent/BR0207649A/pt not_active Application Discontinuation
- 2002-02-26 NZ NZ527764A patent/NZ527764A/en not_active IP Right Cessation
- 2002-02-26 AT AT02744903T patent/ATE434438T1/de active
- 2002-02-26 DK DK02744903T patent/DK1385522T3/da active
- 2002-02-26 PT PT02744903T patent/PT1385522E/pt unknown
2003
- 2003-08-18 IL IL157466A patent/IL157466A/en not_active IP Right Cessation
- 2003-08-25 NO NO20033769A patent/NO325416B1/no not_active IP Right Cessation
2004
- 2004-07-15 HK HK04105220.7A patent/HK1062266A1/xx not_active IP Right Cessation
2009
- 2009-08-28 CY CY20091100900T patent/CY1109347T1/el unknown

Also Published As

Publication number	Publication date
SK287489B6 (sk)	2010-11-08
AU2002308218B2 (en)	2005-11-10
KR100848197B1 (ko)	2008-07-24
ES2326264T3 (es)	2009-10-06
DK1385522T3 (da)	2009-10-12
IL157466A0 (en)	2004-03-28
CA2439268A1 (en)	2002-09-06
RU2003127392A (ru)	2005-03-27
NO20033769D0 (no)	2003-08-25
CN1511036A (zh)	2004-07-07
IL157466A (en)	2012-04-30
WO2002067941A2 (en)	2002-09-06
RU2313345C2 (ru)	2007-12-27
JP4499359B2 (ja)	2010-07-07
PT1385522E (pt)	2009-09-04
US7723339B2 (en)	2010-05-25
PL363288A1 (en)	2004-11-15
US20040132754A1 (en)	2004-07-08
JP2004527493A (ja)	2004-09-09
DE60232719D1 (de)	2009-08-06
MXPA03007729A (es)	2003-12-04
CN1511036B (zh)	2010-05-05
KR20040025900A (ko)	2004-03-26
EP1385522A2 (en)	2004-02-04
SK10712003A3 (sk)	2004-02-03
PL207197B1 (pl)	2010-11-30
ATE434438T1 (de)	2009-07-15
NO20033769L (no)	2003-08-25
WO2002067941A3 (en)	2003-11-20
EP1385522B1 (en)	2009-06-24
CY1109347T1 (el)	2014-07-02
NZ527764A (en)	2006-01-27
HK1062266A1 (en)	2004-10-29
BR0207649A (pt)	2004-03-09
WO2002067941A8 (en)	2003-12-18
CA2439268C (en)	2010-01-19

Legal Events

Date	Code	Title	Description
2014-09-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
RU2330661C2 (ru)	2008-08-10	Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона
US11446309B2 (en)	2022-09-20	Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
NO325416B1 (no)	2008-04-21	Kombinasjon som omfatter en signaltransduksjoninhibitor og et epotilonderivat, farmasoytisk sammensetning som inneholder nevnte kombinasjon, samt anvendelse derav ved behandling av en proliferativ sykdom.
AU2005294320A1 (en)	2006-04-20	Combination of organic compounds
CA2890699A1 (en)	2014-05-15	Combination therapy
AU2002308218A1 (en)	2003-03-06	Combination comprising a signal transduction inhibitor and an epothilone derivative
US20120053559A1 (en)	2012-03-01	Treatment of Proliferative Diseases with Epothilone Derivatives and Radiation
CN112237579B (zh)	2022-03-29	药物组合及其用途
AU2004273605B2 (en)	2008-07-31	Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
TWI343258B (en)	2011-06-11	Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative
CA2918530C (en)	2023-10-03	Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
AU2008200555A1 (en)	2008-02-28	Treatment of proliferative diseases with epothilone derivatives and radiation